Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Keytruda
Marketing
BeiGene launches PD-1 drug Tevimbra at 10% discount to Keytruda
The average wholesale acquisition cost of Tevimbra is estimated to be $15,075 per month, a BeiGene spokesperson told Fierce Pharma.
Angus Liu
Oct 4, 2024 10:37am
Experts back FDA's plan to restrict PD-1 drugs in GI cancers
Sep 26, 2024 1:38pm
FDA challenges broad use of PD-1 drugs in stomach cancer
Sep 24, 2024 2:30pm
Merck's Keytruda helps early-stage TNBC patients live longer
Sep 15, 2024 8:10am
Merck's Keytruda-Lenvima combo triumphs in liver cancer subtype
Sep 14, 2024 10:30am
Merck's Keytruda turns in mixed results in gynecological cancers
Sep 13, 2024 6:05pm